Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

MorphoSys AG Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 6, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	571,626	434,866	270,463	131,124	124,718	131,124
Market Cap Growth	60.79%	60.79%	106.27%	5.14%	-4.88%	125.75%
Enterprise Value	579,297	434,470	315,126	164,781	152,778	150,427
Last Close Price	2025.60	1541.05	955.71	462.02	436.63	456.89
PE Ratio	54.60	41.53	-	44.11	13.24	13.52
Forward PE	25.48	26.02	26.45	10.10	10.59	12.50
PS Ratio	4.25	3.24	2.14	1.13	1.01	1.20
PB Ratio	6.46	4.91	3.45	1.33	1.32	1.86
P/TBV Ratio	7.74	5.89	4.15	1.86	1.83	2.77
P/FCF Ratio	-	-	-	743.80	39.15	36.78
P/OCF Ratio	-	-	-	20.97	11.25	11.59
PEG Ratio	1.27	1.25	1.12	0.63	1.71	1.14
EV/Sales Ratio	4.31	3.23	2.49	1.41	1.24	1.38
EV/EBITDA Ratio	23.50	17.63	17.22	11.53	7.99	7.74
EV/EBIT Ratio	29.27	21.95	21.80	14.48	8.30	8.77
EV/FCF Ratio	-36.73	-	-	934.71	47.96	42.20
Debt / Equity Ratio	0.28	0.28	0.16	0.47	0.42	0.71
Debt / EBITDA Ratio	1.00	1.00	0.64	3.03	1.98	2.45
Debt / FCF Ratio	-	-	-	261.38	12.44	13.99
Asset Turnover	0.88	0.88	0.75	0.64	0.75	0.72
Inventory Turnover	1.57	1.57	1.87	1.81	1.90	1.74
Quick Ratio	0.85	0.85	0.75	1.06	1.08	1.00
Current Ratio	1.56	1.56	1.28	2.10	1.77	1.75
Return on Equity (ROE)	12.54%	12.54%	-20.70%	-0.93%	12.04%	14.77%
Return on Assets (ROA)	8.14%	8.14%	5.36%	3.90%	7.04%	7.08%
Return on Capital (ROIC)	12.13%	12.13%	7.68%	5.11%	9.04%	9.20%
Return on Capital Employed (ROCE)	19.60%	19.60%	16.90%	8.00%	14.80%	15.00%
Earnings Yield	1.83%	2.41%	-5.55%	2.27%	7.55%	7.40%
FCF Yield	-2.76%	-3.63%	-4.30%	0.13%	2.55%	2.72%
Dividend Yield	0.12%	0.16%	0.26%	0.54%	0.57%	0.55%
Payout Ratio	6.73%	6.73%	-	23.68%	9.84%	7.26%
Buyback Yield / Dilution	-0.02%	-0.02%	-0.00%	-	-	-
Total Shareholder Return	0.10%	0.14%	0.26%	0.54%	0.57%	0.55%

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.